A nurse is educating a newly licensed nurse on the purpose of administering vecuronium to a client with severe respiratory distress. What action by the newly licensed nurse indicates a comprehensive understanding of the medication's effects?

A. Correctly identifying that vecuronium is used to facilitate mechanical ventilation: Vecuronium is a nondepolarizing neuromuscular blocking agent that competitively inhibits acetylcholine at nicotinic receptors in the neuromuscular junction. This prevents depolarization of skeletal muscle, resulting in flaccid paralysis. In clients with severe respiratory distress, it is administered to optimize ventilator synchrony and reduce oxygen consumption. B. Mentioning that vecuronium is administered to reduce anxiety in patients with severe respiratory distress: Vecuronium does not have sedative, anxiolytic, or analgesic properties. It produces paralysis without affecting consciousness or pain perception, which is why sedation and analgesia must be administered concurrently. C. Stating that vecuronium is primarily given to treat inflammation: Vecuronium has no anti-inflammatory properties and does not act on immune or inflammatory pathways. Its pharmacologic action is limited to neuromuscular transmission blockade. Inflammatory conditions are treated with corticosteroids or other targeted therapies. D. Indicating that vecuronium is given to treat infections in clients with severe respiratory distress: Vecuronium does not possess antimicrobial activity and does not address infectious processes. Neuromuscular blockers are used to manage ventilation mechanics rather than treat the underlying infection.